Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1

Clinical Infectious Diseases

Volumn 33, Issue 12, 2001, Pages 2049-2054

  Matthews, Gail V ^a   Pillay, Deenan ^a   Cane, Patricia ^b   Ratcliffe, Daina ^b   Gazzard, Brian ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE ALPHA; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG;

ADULT; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROCONVERSION; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION;

2-AMINOPURINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MUTATION; TREATMENT FAILURE;

EID: 0035893186     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322655     Document Type: Article

References (31)

1. Hepatitis B and C in HIV infected patients. Prevalence and prognostic value
2. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection
3. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection
4. Effects of lamivudine on replication of hepatitis B in HIV-infected men
5. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro
6. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
7. Lamivudine as initial treatment for chronic hepatitis B in the United States
8. A one-year trial of lamivudine for hepatitis B
9. Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo-controlled multicentre study in Asia
10. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients
11. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus co-infected persons in a randomized, controlled study (CAESAR)
12. Lamivudine therapy for chronic hepatitis B and HIV coinfection
13. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
14. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine
15. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: An analysis of the CAESAR Study
16. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection
17. Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation
18. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
19. Analysis of HBV quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation
20. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance
21. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
22. Hepatitis-B - Virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
23. Selection of multiresistant hepatitis B virus during sequential nucleoside analogue therapy
24. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
25. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
26. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
27. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy following liver transplantation
28. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
29. Emergence and characterization of lamivudine resistant hepatitis B variant
30. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene
31. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure